Advocates for participants in Medicare Part B such as AARP are arguing that they should be seeing a premium rebate this year, although it’s unlikely that this will happen. The reason: the fund has a large surplus after adding on $21.60/month, a record price increase. It’s estimated that roughly $10/month to cover the cost of the new Alzheimer’s drug Aduhelm. The annual cost of the drug was $28,200 but the Centers for Medicare and Medicaid Services (CMS) refused to cover it even though it received FDA approval and the drug was pulled from the market. “It is unconscionable for a single outrageously priced drug to drive up premiums for all Medicare beneficiaries,” sadid Nancy LeaMond, AARP chief advocacy and engagement officer. She ways savings from Aduhelm should be swiftly returned to Medicare Part B users.
